Clinical trial · no report yet · Phase 2
KEYNOTE-942
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
- NCT03897881 ↗
- Active, not recruiting
- ModernaTX, Inc.
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Podcasts | 26 | |
| X threads | 25 | |
| YouTube | 20 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (KEYNOTE- 942)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Melanoma
- Interventions
- mRNA-4157; Pembrolizumab
- Arms
- mRNA-4157 and Pembrolizumab · Experimental
- Pembrolizumab · Active comparator
- Enrollment
- 267
- Primary outcomes
- Recurrence-Free Survival (RFS), Assessed Using Radiological Imaging
- Sponsor
- ModernaTX, Inc. with Merck Sharp & Dohme LLC
- Start
- Jul 18, 2019
- Primary completion
- Nov 21, 2032 (estimated)
- Results posted
- No
- Registry record
- NCT03897881 · updated Sep 8, 2026
Publications
linked from the registry- Khattak A, Carlino MS, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, Faries M, Tran TT, Cowey CL, Pecora A, Medina T, Atkinson V, Krepler C, Jemielita T, Mao H, Chow J, Ojalvo LS, Mehnert JM; KEYNOTE-942 Investigators. Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study. J Clin Oncol. 2026 Jun 1:JCO2600835. doi: 10.1200/JCO-26-00835. Online ahead of print. PubMed 42223134
- Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, Faries M, Tran TT, Cowey CL, Pecora A, Shaheen M, Segar J, Medina T, Atkinson V, Gibney GT, Luke JJ, Thomas S, Buchbinder EI, Healy JA, Huang M, Morrissey M, Feldman I, Sehgal V, Robert-Tissot C, Hou P, Zhu L, Brown M, Aanur P, Meehan RS, Zaks T. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024 Feb 17;403(10427):632-644. doi: 10.1016/S0140-6736(23)02268-7. Epub 2024 Jan 18. PubMed 38246194